Akebia Therapeutics, Inc. (NASDAQ:AKBA) SVP Michel Dahan sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $19.30, for a total transaction of $96,500.00. Following the completion of the transaction, the senior vice president now owns 97,224 shares in the company, valued at approximately $1,876,423.20. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Michel Dahan also recently made the following trade(s):

  • On Monday, October 2nd, Michel Dahan sold 1,398 shares of Akebia Therapeutics stock. The shares were sold at an average price of $19.64, for a total transaction of $27,456.72.
  • On Tuesday, August 15th, Michel Dahan sold 5,000 shares of Akebia Therapeutics stock. The shares were sold at an average price of $15.00, for a total transaction of $75,000.00.

Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) opened at 19.23 on Thursday. The firm has a 50-day moving average of $17.09 and a 200 day moving average of $13.79. The company’s market capitalization is $351.91 million. Akebia Therapeutics, Inc. has a 52-week low of $7.16 and a 52-week high of $20.25.

Akebia Therapeutics (NASDAQ:AKBA) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.36. The company had revenue of $28.52 million for the quarter, compared to analyst estimates of $26.50 million. On average, analysts anticipate that Akebia Therapeutics, Inc. will post ($2.57) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/05/insider-selling-akebia-therapeutics-inc-akba-svp-sells-96500-00-in-stock.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its holdings in shares of Akebia Therapeutics by 1.2% in the first quarter. Goldman Sachs Group Inc. now owns 49,277 shares of the biopharmaceutical company’s stock valued at $453,000 after purchasing an additional 608 shares during the last quarter. Piermont Capital Management Inc. acquired a new stake in shares of Akebia Therapeutics in the first quarter valued at approximately $595,000. Morgan Stanley raised its holdings in shares of Akebia Therapeutics by 6.8% in the first quarter. Morgan Stanley now owns 870,442 shares of the biopharmaceutical company’s stock valued at $8,008,000 after purchasing an additional 55,369 shares during the last quarter. American International Group Inc. raised its holdings in shares of Akebia Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 22,121 shares of the biopharmaceutical company’s stock valued at $204,000 after purchasing an additional 1,460 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its holdings in shares of Akebia Therapeutics by 6.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 125,130 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 7,353 shares during the last quarter. Institutional investors own 57.62% of the company’s stock.

AKBA has been the topic of several research reports. BidaskClub lowered shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Zacks Investment Research lowered shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. Aegis reiterated a “buy” rating on shares of Akebia Therapeutics in a research note on Friday, June 30th. ValuEngine upgraded shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Royal Bank Of Canada initiated coverage on shares of Akebia Therapeutics in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $17.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $22.00.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Insider Buying and Selling by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Stock Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related stocks with our FREE daily email newsletter.